-

08:11:09 AM

Latest RHHBY Stock Market News

RHHBY - Roche Holding AG

09/22/21 1:00 AM

OTC : RHHBY

Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised. 1-3 Three new molecular diagnostic test panels for influenza and other common respiratory illnesses

RHEA-AI

neutral

09/20/21 9:05 AM

OTC : RHHBY

New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer

Data presented at the 2021 ESMO Virtual Congress and the IASLC 2021 WCLC add to the body of evidence supporting Tecentriq’s role in treating early-stage lung cancer As published in The Lancet, Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the

RHEA-AI

very positive

09/17/21 7:10 AM

OTC : RHHBY

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusion s If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche

RHEA-AI

very positive

09/15/21 1:00 AM

OTC : RHHBY

Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analysis tools Artificial intelligence technology shows promise in advancing pathology imaging, which

RHEA-AI

positive

09/09/21 1:00 AM

OTC : RHHBY

Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021 TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic The acquisition enables Roche to further expand the portfolio of

RHEA-AI

positive

09/07/21 1:00 AM

OTC : RHHBY

conferences

Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers

Genentech, a member of the Roche Group, today announced that new oncology data will be presented at the European Society for Medical Oncology Congress, which will be held September 16-21, 2021. With one of the broadest oncology pipelines and portfolios in the industry, Genentech presentations include late-breaking abstracts featuring data in early-stage...

RHEA-AI

positive

09/07/21 12:00 AM

OTC : RHHBY

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from

RHEA-AI

neutral

08/27/21 11:45 AM

OTC : RHHBY

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the

RHEA-AI

very positive

08/18/21 11:35 AM

OTC : RHHBY

fda approval

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually. 1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021. 1 Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid

RHEA-AI

positive

08/09/21 1:00 AM

OTC : RHHBY

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care

Pivotal phase III POLARIX trial comparing Polivy in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first-line diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of investigator-assessed progression-free survival Prolonging survival without

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next